rawfin.tv
Biogen Raises Full-Year Revenue Forecast on Strong Sales
EarningsstocksAI Generated

Biogen Raises Full-Year Revenue Forecast on Strong Sales

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Biogen has increased its full-year revenue forecast for 2026, citing stronger-than-expected sales, particularly from its multiple sclerosis treatments. The positive outlook is partly attributed to early successes from its Apellis deal.

BiogenRevenue ForecastPharmaceuticalsGuidanceHealthcareBiotech

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks